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ORIGINAL ARTICLE
Clinical validity of plasma and urinary desmosine as
biomarkers for chronic obstructive pulmonary disease
Jeffrey T-J Huang,1,2,3 Rekha Chaudhuri,4 Osama Albarbarawi,1 Alun Barton,1
Christal Grierson,1 Petra Rauchhaus,1 Christopher J Weir,5 Martina Messow,6
Nicola Stevens,3 Charles McSharry,4 Giora Feuerstein,2 Somnath Mukhopadhyay,7
Jeffrey Brady,1,2,3 Colin N A Palmer,3 Douglas Miller,2 Neil C Thomson4
ABSTRACT
Background Although an increased concentration of
degraded elastin products in patients with chronic
obstructive pulmonary disease (COPD) has been reported
for many years, its clinical validity and utility remain
uncertain due to technical difficulties, small study groups
and the unknown relationship between exacerbation and
elastin degradation. The objectives of this study were to
determine the validity of urinary and blood total
desmosine/isodesmosine in patients with COPD and
asthma and to evaluate their relationship to exacerbation
status and lung function.
Methods Urinary and blood desmosine levels were
measured using validated isotopic dilution liquid
chromatographyetandem mass spectrometry methods.
Results 390 study participants were recruited from the
following groups: healthy volunteers, stable asthma,
stable and ‘during an exacerbation’ COPD. Compared
with healthy non-smokers, we found increased urinary or
blood desmosine levels in patients with COPD, but no
differences in patients with asthma or healthy
smokers. The elevation of urinary desmosine levels
was associated with the exacerbation status in patients
with COPD. Approximately 40% of patients with stable
and ‘during an exacerbation’ COPD showed elevated
blood desmosine levels. Blood desmosine levels were
strongly associated with age and were negatively
correlated with lung diffusing capacity for carbon
monoxide.
Conclusion The results suggest that urinary desmosine
levels are raised by exacerbations of COPD whereas
blood desmosine levels are elevated in a subgroup of
patients with stable COPD and reduced lung diffusing
capacity. The authors speculate that a raised blood
desmosine level may identify patients with increased
elastin degradation suitable for targeted therapy. Future
prospective studies are required to investigate this
hypothesis.
INTRODUCTION
Pulmonary emphysema, the destruction of elastic
tissue in alveolar septae of the lung, is known to
affect 12e28% of patients with chronic obstructive
pulmonary disease (COPD)1 and is thought to
represent an end result of the proteinasee
antiproteinase imbalance associated with aberrant
inﬂammation.2 There is no early diagnostic tool
available to stratify at-risk patients with elevated
elastin degradation. Such a tool could be critical for
the development of intervention strategies to
prevent disease progression.
The analysis of turnover of mature elastin may
offer promising potential as a surrogate marker for
lung destruction and for testing the efﬁcacy of
agents with the potential to reduce elastin break-
down. Two isomeric pyridinium-based amino acids,
desmosine (DES) and isodesmosine (IDS) resulting
from the condensation of four lysine residues
between elastin proteins by lysyl-oxidase, represent
ideal biomarkers for monitoring elastin turnover
because these special cross-links are only found in
mature elastin in mammals.3 The release of these
two compounds and DES-containing or IDS-
containing peptides into body ﬂuids has been used
to estimate levels of elastin degradation in diseases
such as COPD.4 Despite being one of the most
promising biomarkers linking directly to the path-
ophysiology, the clinical validity and utility of urine
and blood total DES/IDS (uDES and bDES) as
biomarkers for COPD remains unproven. The
major reasons are issues related to analytical
validity (including sensitivity, speciﬁcity, inac-
curacy) of assays, small study groups,4 and the lack
of large longitudinal studies to determine the
predictive power of uDES and bDES for patients’
clinical outcome.
Key messages
What is the key question?
< Are urinary and plasma desmosine useful
biomarkers of disease in chronic obstructive
pulmonary disease (COPD) and asthma, taking
account of smoking and exacerbation status.
What is the bottom line?
< Plasma desmosine concentrations are elevated
in patients with stable COPD but reduced lung
diffusing capacity. Urinary desmosine concen-
trations are raised during exacerbations of
COPD.
Why read on?
< This study using improved validity of analytical
assays and substantial patient numbers
describes the value of urinary and plasma
desmosine as a biomarker of disease activity
in COPD.
< Additional materials are
published online only. To view
these files please visit the
journal online (http://thorax.bmj.
com/content/67/6.toc).
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Analytical speciﬁcity has been one of the key problems for
methodologies such as immunoassays,5e8 capillary electro-
phoresis,9e12 electrokinetic chromatography,13 and to a lesser
degree, high-performance liquid chromatography isotope
dilution.14e17 Liquid chromatographyetandem mass spectrom-
etry (LC-MS/MS) methods are believed to provide the best
speciﬁcity and sensitivity.4 However, mass spectrometry is not
intrinsically quantitativedoften matrix compounds in the
complex samples interact with the analytes in the MS ion source
resulting in variability that adversely impacts data quality. To
address this issue, our laboratory has developed and analytically
validated reliable isotope dilution LC-MS/MS methods for
DES/IDS measurement.18
Using these validated methods, the primary aim of this study
was to examine the clinical validity of uDES and bDES as
phenotyping biomarkers for COPD. The secondary goals were to
investigate the relationships of uDES and bDES levels to smoking
status, disease entity, severity, exacerbations and lung function.
METHODS
Study participants
Volunteers were recruited from the hospital respiratory clinics
and from general practices in Glasgow (Glasgow COPD and
Asthma Biomarker study; group 1) and Dundee (group 2).
Potentially eligible patients were identiﬁed by scrutiny of
hospital records, from general practice asthma clinic registers, by
advertisements in local papers and from computerised general
practice records. For group 1, 306 patients were screened for the
study and 204 met the required inclusion and exclusion criteria.
All study participants gave their written informed consent and
the original study was approved by the local ethics committees
and Institutional Review Board.
Participants were recruited from the following groups:
< Stable COPD: age range 40e80 years and duration of COPD
$6 months; symptoms of cough and breathlessness, history
of smoking over 10 pack years; forced expiratory volume in
1 s (FEV1)/forced vital capacity (FVC) post bronchodilator
<70%; FEV1 30e80% predicted with reversibility to 2.5 mg
salbutamol of <200 ml; exacerbation free for 4 weeks and no
chest infection for 2 weeks.
< COPD during an exacerbation: age range 40e80 years and
duration of COPD $6 months; symptoms of cough and
breathlessness, current or past history of smoking >10 pack
years; all participants were hospitalised because of the
exacerbation.
< Stable asthma: age range 18e75 years and duration of asthma
$6 months; symptoms of episodic wheezing chest tightness
and/or dyspnoea (see online supplementary information for
further details); on stable medication for 4 weeks and no
exacerbation for 4 weeks or chest infection for 2 weeks;
deﬁnition of smokers, $10 pack years and currently smoking
at least give cigarettes per day.
< Healthy controls (smokers and non-smokers): age range
18e80 years; no known respiratory disease or recent (in last
2 weeks) chest infection; normal spirometry (FEV1/FVC
>80%; FEV1 > 80% predicted); no chronic respiratory
symptoms; no known exposure to passive smoke in the 4 h
prior to performing the tests in healthy non-smokers based
on history and further examination by serum cotinine level
(median (IQR: Q1eQ3)¼0.9 (0.3e1.1) ng/ml).
Sample collection
The majority of participants (group 1) had spot urine, blood and
sputum samples collected during two visits to establish the
stability of uDES and bDES levels in each group. The remaining
participants (group 2) had spot urine and sputum or blood
samples collected (see online supplementary information for
further details).
uDES, bDES and sputum matrix metalloproteinase-9 activity
assays
uDES and urinary creatinine assays were carried out using
validated isotope dilution LC-MS/MS methods.18 Similarly
bDES concentration was analysed using a modiﬁed assay with
10 times the lower limit of quantiﬁcation. The uDES levels were
expressed as uDES concentration normalised to urinary creati-
nine concentration according to previous reports.4 The matrix
metalloproteinase-9 (MMP-9) activity kit was purchased from
R&D systems (Abingdon, UK) and has been validated for use in
sputum supernatant. The assay performance can be found in
supplementary online table E1.
Lung function measurements
Spirometry was performed to American Thoracic Society
guidelines. Transfer factor of the lung for carbon monoxide
(TLCO%) was measured using the body box technique (Zan500
Body Plethysmography, nSpire Health Ltd, Hertford, UK) and
corrected for haemoglobin and carboxy haemoglobin in patients
with stable asthma and COPD.
Data analysis
Peak area under the curve for DES/IDS and D5-DES, calibration
curve, SD, coefﬁcient of variation (CV) and % bias were gener-
ated and calculated by LCquan (ThermoFisher, Hemel Hemp-
stead, UK). Data normality was examined using the Shapiro-Wilk
test to determine the use of parametric or non-parametric tests.
Two sample t test, ManneWhitney U test, one-way analysis of
variance (ANOVA), KruskaleWallis ANOVA and Spearman
correlation were performed using Prism 5.04 or SPSS V.17.0 as
appropriate.
RESULTS
Clinical characteristics of study groups
We investigated uDES and bDES levels in a total of 390 partic-
ipants in two study groups: group 1 comprised ﬁve subgroups,
including 26 healthy non-smokers, 20 healthy smokers, 53 stable
asthma non-smokers, 56 stable asthma smokers, and 53 patients
with stable COPD (table 1); group 2 comprised two subgroups
including 81 healthy volunteers and 105 patients with COPD at
the time of an exacerbation (table 2). In the asthma and stable
COPD groups, patients with different severities (ie, mild,
moderate and severe) were equally distributed so that the rela-
tionship between DES levels and increasing disease severity can
be investigated. The average age of patients with COPD in
group 1 and group 2 (urine and sputum) was signiﬁcantly older
compared with the other groups (p<0.001, table 1 and 2). There
was a higher percentage of men in the healthy volunteers in the
blood samples of group 2.
uDES levels in patients with stable asthma, stable and ‘during an
exacerbation’ COPD and healthy volunteers
In group 1, there was no signiﬁcant difference in uDES levels
between smokers and non-smokers in both healthy volunteers
and patients with asthma (ﬁgure 1A and table 1). In addition,
we did not observe a difference between healthy volunteers and
patients with asthma (ﬁgure 1A and table 1). uDES levels were
not associated with serum cotinine levels in healthy volunteers
(r¼0.02, Spearman correlation).
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In COPD groups, patients with stable COPD excreted
aw37% higher level of uDES compared with non-smokers with
asthma (p<0.01, group 1) but no difference was found between
the stable COPD group and healthy non-smokers or smokers
(table 1). Similar results were found at a subsequent visit (see
online supplementary table E2). Patients with ‘during an
exacerbation’ COPD, however, had signiﬁcantly higher uDES
levels compared with other subgroups (p<0.001, ﬁgure 1A and
table 2). No signiﬁcant difference was found between non-
smokers, current smokers and ex-smokers in the ‘during an
exacerbation’ COPD group (p¼0.11; see online supplementary
table E3). There was no correlation between uDES levels and
age, gender or body mass index (data not shown). These results
suggest that the elevation of uDES levels only occurs in COPD
at the time of an exacerbation, whereas during clinical stable
disease, the uDES levels remain normal.
bDES levels in patients with stable asthma, stable and
exacerbated COPD and healthy volunteers
Similar to the ﬁndings on uDES, the bDES levels were no
different among healthy smokers and non-smokers, smokers
with asthma and non-smokers with asthma in group 1 (table 1
and ﬁgure 1B). bDES levels were not signiﬁcantly correlated
with serum cotinine levels in healthy volunteers (r¼0.01,
Spearman correlation). Interestingly, in contrast to little or no
change in uDES levels, the bDES levels in these patients with
stable COPD were signiﬁcantly elevated compared with healthy
non-smokers and smokers (p<0.001, table 2 and ﬁgure 1B). The
bDES levels between patients with stable and ‘during an exac-
erbation’ COPD were similar. Despite the distinct distribution of
these two measurements according to the patient’s exacerbation
status, the levels of uDES and bDES were found to be positively
correlated in both stable (r¼0.33, p<0.001, Spearman
Table 1 Demographic and desmosine data for group 1 consisting of healthy volunteers and patients with stable chronic obstructive pulmonary
disease (COPD) and asthma
Sample type
Group 1
Blood, urine and sputum
Group
Healthy volunteers:
non-smokers
Healthy volunteers:
smokers
Asthma:
non-smokers
Asthma:
smokers Stable COPD
Number of participants 26 20 53 56 53
Gender (M/F) 8/18 9/11 22/31 27/29 23/30
Smoking status (smokers/
ex-smokers/non-smokers)
0/0/26 20/0/0 0/0/53 56/0/0 28/25/0
Age (years) 51613 5269 46612 47610 6567*
Body mass index 27 (22e28) 27 (21e30) 28 (25e36) 26 (23e30) 27 (23e30)
FEV1 (% predicted) 106 (95e115) 93 (88e100) 79 (70e91)y 78 (58e93)y 62 (44e77)z
TLCO%COHb NA NA 86611 77618x 60615{
uDES (ng/mg creatinine) 9 (8e13) 11 (9e15) 8 (6e10) 10 (7e13) 11 (9e15)**
bDES (ng/ml) 0.21 (0.19e0.24) 0.23 (0.19e0.26) 0.21 (0.19e0.25) 0.22 (0.19e0.25) 0.29 (0.24e0.35)*
Data are shown as median (IQR) or mean 6 SD based on whether data were normally distributed. KruskaleWallis analysis of variance (ANOVA) with Dunn’s method for pairwise multiple
comparison or one-way ANOVA with Tukey’s method was used.
*p<0.001, versus other four groups.
yp<0.05, versus healthy non-smokers and smokers.
zp<0.001 versus healthy non-smokers and smokers; p<0.05 versus non-smokers and smokers with asthma.
xp<0.001, versus non-smokers with asthma and patients with COPD.
{p<0.001, versus non-smokers and smokers with asthma.
**p<0.01 versus non-smokers with asthma.
bDES, blood desmosine; FEV1, forced expiratory volume in 1 s; TLCO%COHb, transfer factor corrected for haemoglobin and carboxy haemoglobin; uDES, urinary desmosine.
Table 2 Demographic and desmosine data for group 2 consisting of healthy volunteers and patients with an exacerbation of chronic obstructive
pulmonary disease (COPD)
Sample type
Group 2
Urine and sputum Blood
Group Healthy volunteers (HV2a)
Patients with ‘during
an exacerbation’ COPD Healthy volunteers (HV2b)
Patients with ‘during
an exacerbation’ COPD
Number of participants 62 50* 19 102*
Gender (M/F) 24/38 24/26 18/1 43/59
Smoking status (smokers/e-smokers/
non-smokers/unknown)
13/41/8/0 31/2/15/2 10/0/9/0 55/33/0/14
Age (years) 22 (21e45) 69 (60e74)y 68 (65e73) 72 (66e79)
Body mass index 2564 2667 NA 2667
FEV1 (% predicted) 103613 39616y NA 47618
uDES (ng/mg creatinine) 8 (6e10) 16 (14e22)y e e
bDES (ng/ml) e e 0.17 (0.12e0.23) 0.30 (0.21e0.37)y
Data are shown as median (IQR) or mean 6 SD.
Note that healthy volunteers recruited for urine and sputum analysis (HV2a) were different from those for blood analysis (HV2b).
*A total of 47 patients with ‘during an exacerbation’ COPD were the same as those who had urine, sputum and blood collected.
yp<0.001, versus healthy volunteers, ManneWhitney test.
bDES, blood desmosine; FEV1, forced expiratory volume in 1 s; uDES, urinary desmosine.
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correlation) and ‘during an exacerbation’ COPD (r¼0.38,
p¼0.01) (ﬁgure 1C). These results suggest that elevated bDES
levels are speciﬁc to COPD and occur when patients are
clinically stable or at the time of an exacerbation.
Increased bDES levels, however, were not observed in all
patients with COPD (ﬁgure 1). Twenty-two of 52 (42%)
patients with stable COPD showed an elevated bDES concen-
tration based on a nominal cut-off of 0.30 ng/ml (deﬁned by the
upper limit of a 95% prediction interval for desmosine values in
all healthy non-smokers) on at least one visit. Among these
patients, 17 of 48 (35%) appeared to express elevated levels of
bDES on both visits despite the intra-subject variability being
signiﬁcantly increased (see online supplementary ﬁgure E1).
A similar observation was found in the ‘during an exacerbation’
COPD group in which 46 of 102 (45%) had values above the
cut-off.
The association among uDES levels, proteinuria and lung
inflammation in patients with ‘during an exacerbation’ COPD
We postulated that the cause of higher urinary excretion of
degraded elastin products in patients with ‘during an exacerbation’
COPD is due to compromised renal capillary endothelial perme-
ability. Among factors occurring during COPD exacerbations,
acute inﬂammation is known to affect renal capillary endothelial
permeability leading to proteinuria or albuminuria.19 20 To inves-
tigate this possibility, we measured MMP-9 activity, a parameter
known to be associated with acute airway inﬂammation,21 in the
sputum samples taken from the same patients during the same
visit. As expected, a much higher (on average 10-fold) sputum
MMP-9 activity was observed in patients with ‘during an exac-
erbation’ COPD compared with healthy volunteers in group 2
(p<0.001, ﬁgure 2A) while patients with stable COPD only
showed a moderate 36% increase compared with healthy volun-
teers in group 1 (p¼0.05, ﬁgure 2A). The increased sputumMMP-9
activity correlated with the uDES concentration (ﬁgure 2B). The
results support the hypothesis that many patients with ‘during an
exacerbation’ COPD had an acute inﬂammatory response. In line
with this hypothesis, urinary protein concentration in these
patients was also found to be signiﬁcantly higher (p<0.001,
compared with healthy volunteers and patients with stable
COPD, ﬁgure 2C), whereas there were no differences among the
stable COPD and other subgroups in group 1 (p¼0.7e1.0). In
addition, we found that urinary protein concentration in all
groups was highly correlated with non-normalised uDES level
(r¼0.79, p<0.0001, Spearman correlation, ﬁgure 2C). When
the normalisation of uDES is based on urinary protein concen-
tration (instead of creatinine as normally performed), no
difference between healthy volunteers and patients with ‘during
an exacerbation’ COPD was observed (p¼0.97, ﬁgure 2D).
Intra-subject variability of uDES and bDES levels
Intra-subject variability in uDES and bDES levels between the
two visits over a period of 6e8 weeks was assessed using CVand
Bland Altman plot for each participant. The intra-subject vari-
ability of bDES was relatively smaller (average CV¼6e12%)
compared with uDES (41e50%) in healthy volunteers and
patients with COPD (see online supplementary ﬁgure E1). The
Bland-Altman plots suggest that the bDES levels were stable
between visits and that the limits of agreement may be different
(in absolute terms) between the groups.
Association of bDES with clinical variables
The potential correlations of bDES with clinical variables
(age, gender, smoking pack years, blood cotinine levels, FEV1
Figure 1 Urinary and blood desmosine (uDES and bDES) levels
in patients with stable asthma, stable chronic obstructive
pulmonary disease (COPD), ‘during an exacerbation’ COPD and
healthy volunteers. uDES (A) and bDES levels (B) were analysed in
a total of 390 participants from six subgroups including healthy
non-smokers, healthy smokers, non-smokers with stable asthma,
smokers with stable asthma, patients with stable COPD and patients
with ‘during an exacerbation’ COPD. **p<0.001, patients with ‘during an
exacerbation’ COPD versus healthy volunteers. #p<0.001, patients with
stable COPD versus healthy non-smokers, healthy smokers, non-
smokers with asthma or smokers with asthma. The boundary of the box
indicates the 25th and 75th percentile and the line within the box marks
the median. Whiskers indicate the 90th and 10th percentiles. Note that
healthy volunteers in group 2 recruited for uDES analysis were different
from those for bDES analysis (table 1). (C) The relationship between
uDES and bDES in healthy non-smokers, smokers, patients with stable
COPD (from group 1) and patients with ‘during an exacerbation’ COPD
(from group 2). The correlation coefficient and p values expressed as r, p
for Spearman correlation were 0.53, <0.001; 0.18, 0.33; 0.50, <0.001;
and 0.38, 0.01 for healthy non-smokers, healthy smokers, patients with
stable COPD, and patients with ‘during an exacerbation’ COPD,
respectively.
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(% predicted), FEV1/FVC and transfer factor corrected for
haemoglobin and carboxy haemoglobin (TLCO%COHb) were
examined. Age and TLCO%COHb were the only two variables
signiﬁcantly associated with bDES levels. bDES levels were
positively correlated with age in healthy volunteers (r¼0.42,
p¼0.02, Spearman correlation), in patients with stable COPD
(r¼0.54, p<0.001) and in patients with exacerbated COPD
(r¼0.48, p<0.001) (ﬁgure 3). The age-related association was
also found in smokers with asthma but did not reach statistical
signiﬁcance in non-smokers with asthma (r¼0.34 and 0.23,
p¼0.01 and 0.08, respectively).
TLCO%COHb was also found to be negatively associated
with bDES levels in patients with stable COPD (r¼0.31,
p¼0.02, partial Spearman correlation controlled for age)
(ﬁgure 4). In the non-smokers and smokers with asthma, the
association was not signiﬁcant (p¼0.21 and 0.55, respectively,
age controlled).
We did not observe a signiﬁcant correlation between FEV1 (%
predicted) and bDES in patients with stable or ‘during an
exacerbation’ COPD (see online supplementary ﬁgure E2). The
data suggest that bDES levels may represent disease activity at
the time rather than disease severity as assessed by baseline
FEV1.
DISCUSSION
In the current study, we evaluated the clinical validity of bDES
and uDES as biomarkers for COPD in the largest study of its
kind to date, using validated isotope dilution LC-MS/MS
methods. With the advantages in analytical validity of assays
and study size, we demonstrated that the elevation of bDES and
uDES levels was speciﬁc to COPD (but not asthma or smoking
status); approximately 40% of patients had elevated bDES levels
in stable COPD and during exacerbation groups; the association
between bDES levels and decreased diffusing capacity of the
Figure 2 The elevated urinary
desmosine (uDES)/creatinine level in
patients with ‘during an exacerbation’
chronic obstructive pulmonary disease
(COPD) is associated with elevated
urinary protein and increased sputum
matrix metalloproteinase-9 (MMP-9)
activity. (A) Sputum MMP-9 activity
(normalised to total protein
concentration) was measured in healthy
volunteers and patients with COPD in
groups 1 and 2; *p¼0.05, yp<0.001,
ManneWhitney U test. Note that
healthy volunteers in group 1 include
healthy smokers and non-smokers
(table 1). The boundary of the box
indicates the 25th and 75th percentile
and the line within the box marks the
median. Whiskers indicate the 90th and
10th percentiles. (B) The relationship
between sputum MMP-9 and uDES
levels in healthy volunteers (group 2,
HV2a), patients with stable COPD and
patients with ‘during an exacerbation’
COPD. A significant correlation was
found between these two
measurements when all participants
were included (r¼0.57, p<0.001,
Spearman correlation). (C) The
un-normalised uDES level was highly
correlated with urinary protein concentration (p<0.001, r¼0.78, 0.63, 0.49 for healthy volunteers (group 2, HV2a), patients with stable COPD and
patients with ‘during an exacerbation’ COPD, respectively; Spearman correlation). Urinary protein concentration was significantly elevated in patients
with ‘during an exacerbation’ COPD in group 2 (p<0.001 vs healthy volunteers, ManneWhitney U test). (D) No difference was observed between
healthy volunteers and patients with ‘during an exacerbation’ COPD in group 2 when uDES levels were normalised to urinary protein levels; p¼0.97,
two sample t test. The top boundary of the bar indicates the mean and the error bar indicates the SD.
Figure 3 The relationship of age and blood desmosine (bDES) levels in
healthy non-smokers, healthy smokers, patients with stable chronic
obstructive pulmonary disease (COPD) and patients with ‘during an
exacerbation’ COPD. The correlation coefficients for healthy volunteers,
patients with stable COPD and patients with ‘during an exacerbation’
COPD were 0.42, 0.54 and 0.48, respectively (Spearman correlation).
The p values were all <0.001. Note that there was a steeper gradient
and higher ‘patient-to-patient’ variation in patients with stable COPD and
‘during an exacerbation’ COPD compared with healthy volunteers.
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lungs in the stable COPD group points to a potential link
between this blood biomarker and lung pathophysiology; in
contrast to bDES, uDES levels were associated with patients’
exacerbation status or with proteinuria which we speculate
might be caused by acute inﬂammation during the course of an
exacerbation.
The interest in using DES/IDS as a surrogate endpoint in
clinical trials for COPD has recently been revived after the
previously unsuccessful attempts to use uDES in the determi-
nation of therapeutic response (or efﬁcacy) following drug
treatments in patients with COPD4 22 and a1-anti-trypsin
deﬁciency.23 24 The growing interest is mainly due to the
technical feasibility of measuring plasma and sputum
DES/IDS levels, which requires assays of high sensitivity and
speciﬁcity.25e27 In particular, Ma and colleagues’ recent study
showed that the long-acting anti-muscarinic bronchodilator
tiotropium bromide reduced the DES/IDS levels in sputum and
blood but not (total) uDES levels in patients with COPD over
a 2-month period.25 Despite there being a potential bias in the
LC-MS/MS method used in that study (as no internal standard
was used), the results support the view that bDES (and perhaps
sputum DES) is a better surrogate endpoint biomarker than
uDES. In those earlier studies6 22e24 where uDES levels were
measured to test drug efﬁcacy in patients with clinically stable
COPD, it is possible that the negative results observed were
simply a combined result of the ‘wrong’ matrix (urine) and
methods used. Without compromised renal capillary endothelial
permeability, changes of elastin degradation over time may not
be detectable in urine.
Our study suggests that approximately 40% of patients with
COPD regardless of exacerbation status have elevated bDES
levels based on a cut-off of 0.30 ng/ml. We speculate that these
patients may have increased elastin degradation based on the
positive association with diffusing capacity for carbon
monoxide. DES-containing and IDS-containing peptides have
been shown to be rapidly accumulated in kidney and slowly
released to urine in animal models.28 As we did not ﬁnd signs of
compromised renal function, for example, increased urinary
protein/creatinine ratio in patients with stable COPD, we do
not believe it was the cause of increased bDES levels. Targeting
such a subgroup may have clinical signiﬁcance in disease prog-
noses or the selection of treatment strategy, especially for the
compounds targeting proteases and inﬂammation. The site of
origin of abnormal elastin degradation in those 40% of patients
with COPD remains to be investigated. Patients with
COPD also have comorbidities such as cardiovascular disease,
which may potentially affect bDES levels as mature elastin is
highly expressed in blood vessels.29 To be able to use bDES
as a surrogate endpoint and prognostic biomarker, further
large longitudinal studies are needed to demonstrate the
relationship between its levels and long-term clinical outcomes,
particularly in the decline of lung function and development of
emphysema.
It is unexpected and interesting that bDES levels in patients
with COPD during an exacerbation did not differ from those of
patients with stable COPD despite the fact that many of these
patients had increased airway inﬂammation as suggested by the
elevated sputum MMP-9 activity. One potential explanation is
that an increased ﬁltration rate to the urine during an exacer-
bation helps the clearance of degraded elastin products in the
blood. Consequently, the bDES levels observed in patients
with COPD during an exacerbation could be underestimated.
The sum of blood and urinary desmosine levels (multiplied by
the volume) may be a useful index to estimate total elastin
breakdown.
Urinary DES and bDES concentrations in patients with
chronic asthma, including a subgroup who were smokers, were
not elevated, which is in keeping with the ﬁnding that most
patients with asthma do not develop emphysema. Whether
exacerbations of asthma, particularly in those who smoke,
increase uDES and bDES concentrations was not investigated in
this study.
We recognise that there were limitations in this study, such as
its cross-sectional nature, limited visit numbers and confounding
factors, for example, corticosteroid and/or antibiotic treatment
during admission in the ‘during an exacerbation’ COPD
group. Further investigation in a longitudinal cohort is required
with baseline measurements and then during and after an
exacerbation.
In summary, this study has demonstrated that the elevation
of uDES or bDES levels was only signiﬁcant in patients with
COPD, but not in those with asthma or healthy smokers. The
elevation of uDES level, however, was only observed during an
exacerbation of COPD but not in stable COPD. We found that
blood desmosine levels are elevated in a subgroup of approxi-
mately 40% of patients with stable COPD. We speculate that
a raised blood desmosine level may identify patients with
increased elastin degradation suitable for targeted therapy.
Future prospective studies are required to investigate this
hypothesis.
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